Related Experiment Video
Updated: Jan 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Atrial Dilated Cardiomyopathy: From Molecular Pathogenesis to Clinical Implications
Maria Cristina Carella1,2, Marco Maria Dicorato1, Vincenzo Ezio Santobuono1
1Cardiovascular Disease Section, Interdisciplinary Department of Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium, Polyclinic of Bari, 70124 Bari, Italy.
Insights
Atrial standstill, an ultrarare heart condition, involves complete loss of atrial function and increases clotting risk. Genetic testing for NPPA mutations is vital for early diagnosis and preventing severe outcomes.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Atrial dilated cardiomyopathy leading to atrial standstill is an ultrarare disorder.
- Characterized by complete loss of atrial electrical and mechanical activity, it carries a high thromboembolic risk.
- The condition presents with absent P waves on ECG and a bradycardic junctional escape rhythm.
Purpose of the Study:
- To elucidate the genetic underpinnings and clinical characteristics of atrial standstill.
- To highlight the importance of early diagnosis and genetic screening for NPPA-related atrial cardiomyopathy.
- To emphasize the need for tailored management strategies, including anticoagulation and pacemaker implantation.
Main Methods:
- Review of clinical cases and genetic analysis.
- Identification and characterization of the homozygous c.449G>A (p.Arg150Gln) mutation in the Natriuretic Peptide A (NPPA) gene.
- Phenotypic description of affected individuals and their heterozygous relatives.
Main Results:
- The homozygous NPPA mutation causes a severe atrial phenotype with biatrial enlargement and progressive atrial inexcitability.
- Heterozygous carriers are typically asymptomatic, underscoring the recessive inheritance pattern.
- Clinical course involves supraventricular arrhythmias, valvular regurgitation, and often requires permanent pacemaker and lifelong anticoagulation.
Conclusions:
- Recognition of atrial standstill as a distinct entity is crucial for timely intervention.
- Genetic screening in patients with unexplained atrial dysfunction can guide precision medicine and improve risk stratification.
- Early diagnosis and management are essential to prevent adverse outcomes in this rare condition.
Abstract:
Atrial dilated cardiomyopathy with progression to atrial standstill is an ultrarare arrhythmogenic disorder characterized by complete loss of atrial electrical and mechanical activity. This condition, which may occur sporadically or in familial clusters, is associated with a markedly increased thromboembolic risk. The electrocardiographic hallmark is the absence of P waves combined with a bradycardic junctional escape rhythm. Biatrial enlargement gradually evolves into giant atria with preserved biventricular systolic function, while supraventricular arrhythmias and progressive atrial inexcitability dominate the clinical course. Valvular regurgitation frequently worsens in parallel with atrial remodelling, and patients often require permanent pacemaker implantation as well as lifelong anticoagulation. Among the few genetic determinants identified, the homozygous c.449G>A (p.Arg150Gln) mutation in the Natriuretic Peptide A gene represents one of the best characterized mechanisms. Disertori et al. first reported this pathogenic variant in 13 affected individuals from Italian families, establishing a recessive inheritance pattern. More recently, Silva et al. and Forleo et al. described additional cases, expanding the phenotypic spectrum of NPPA-related atrial cardiomyopathy. These findings confirm that homozygous carriers develop a severe atrial phenotype, whereas heterozygous relatives typically remain asymptomatic, underlining the importance of genetic testing in young patients with unexplained atrial fibrillation or standstill. Recognition of atrial cardiomyopathy as a distinct clinical entity is crucial, since early diagnosis may guide timely anticoagulation, arrhythmia management, and tailored follow-up. Broader adoption of genetic screening in patients with isolated atrial dysfunction could support precision medicine approaches, improve risk stratification, and ultimately prevent adverse outcomes in this ultrarare but highly morbid condition.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction

